CVS Health (CVS) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• CVS Health is expected to report Q3 2026 results before Wednesday’s market open, with analysts forecasting $1.66 in earnings per share and $104.72 billion in revenue. The company’s FY 2026 EPS guidance is $7.90–$8.10.
• CVS exceeded estimates in its most recent quarter, posting $2.58 EPS versus the $1.87 consensus and $106.10 billion in revenue, up 7.3% year over year.
• Wall Street maintains a favorable view, with a “Moderate Buy” consensus and a $107.80 target price, though investors are watching Aetna margin recovery, declining membership, 340B pressures and potential labor and regulatory risks.

CVS Health (NYSE:CVS - Get Free Report) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect CVS Health to announce earnings of $1.66 per share and revenue of $104.72 billion for the quarter. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Parties can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. The company had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. CVS Health's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.81 EPS. On average, analysts expect CVS Health to post $8.02 EPS for the current fiscal year and $8.51 EPS for the next fiscal year.

CVS Health Price Performance

CVS stock opened at $91.11 on Wednesday. The business's 50-day moving average is $91.46 and its two-hundred day moving average is $88.62. The firm has a market capitalization of $116.53 billion, a P/E ratio of 24.10 and a beta of 0.60. CVS Health has a 1 year low of $69.51 and a 1 year high of $110.68.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be given a dividend of $0.6650 per share. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health's payout ratio is currently 70.37%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on CVS shares. Wells Fargo & Company upped their target price on shares of CVS Health from $103.00 to $123.00 and gave the stock an "overweight" rating in a research note on Monday, July 13th. Piper Sandler set a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Robert W. Baird set a $107.00 price target on shares of CVS Health in a report on Thursday, August 6th. BMO Capital Markets set a $112.00 price target on shares of CVS Health in a report on Wednesday, September 9th. Finally, Argus increased their price objective on shares of CVS Health from $104.00 to $114.00 and gave the company a "buy" rating in a research report on Wednesday, August 19th. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, CVS Health has a consensus rating of "Moderate Buy" and a consensus target price of $107.80.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expected to benefit from a recovery in Aetna’s margins and continued earnings improvement. Its full-year 2026 outlook calls for EPS of approximately $7.90–$8.10, supporting the view that profitability is recovering after several difficult years. Should You Buy CVS Health Stock While It's Under $100?
• Positive Sentiment: The company is expanding its retail assortment to include more Pokémon products, collectibles, toys and seasonal merchandise. Management expects adult demand for collectibles to create additional front-store sales opportunities. CVS wants to sell more Pokémon, collectibles
• Neutral Sentiment: Investors are awaiting CVS’s third-quarter 2026 report. Aetna margin recovery and digital investments could support results, but the company continues to face 340B-related pressure and declining membership, making the earnings outlook mixed. CVS Health Q3 Earnings Preview
• Neutral Sentiment: A shareholder-law firm is soliciting CVS investors regarding potential breaches of fiduciary duties. The notice does not establish wrongdoing, but it could add headline and litigation risk. Shareholder fiduciary-duty inquiry
• Negative Sentiment: CVS pharmacy workers in Rhode Island rallied over staffing and contract issues, highlighting potential labor disruption, wage pressure and service-quality concerns. CVS workers in Rhode Island rally
• Negative Sentiment: Health insurers are challenging Medicaid rating requirements in Georgia. Any unfavorable outcome could increase compliance costs or pressure reimbursement economics for insurers, including CVS’s Aetna business. Georgia Medicaid rating challenges

CVS Health Company Profile

CVS Health Corporation NYSE: CVS is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company's Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.